2018
Monoacylglycerol lipase inhibitors reverse paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy-induced neuropathy
Curry Z, Wilkerson J, Bagdas D, Kyte S, Patel N, Donvito G, Mustafa M, Poklis J, Niphakis M, Hsu K, Cravatt B, Gewirtz D, Damaj M, Lichtman A. Monoacylglycerol lipase inhibitors reverse paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy-induced neuropathy. Journal Of Pharmacology And Experimental Therapeutics 2018, 366: jpet.117.245704. PMID: 29540562, PMCID: PMC6038031, DOI: 10.1124/jpet.117.245704.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsApoptosisBenzodioxolesBiomarkersCarbamatesCell Line, TumorCell ProliferationChemokine CCL2Disease Models, AnimalDose-Response Relationship, DrugEnzyme InhibitorsHumansHyperalgesiaInflammationMaleMiceMonoacylglycerol LipasesNociceptionP38 Mitogen-Activated Protein KinasesPaclitaxelPhosphoproteinsPiperidinesReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2SuccinimidesConceptsAntinociceptive effectPaclitaxel-induced mechanical allodyniaPaclitaxel-induced neuropathic painH460 non-small cell lung cancer cellsNon-small cell lung cancer cellsMonoacylglycerol lipaseMonocyte chemoattractant protein-1Chemotherapy-induced neuropathyPaclitaxel-induced allodyniaPain side effectsPrimary hydrolytic enzymesCell lung cancer cellsSpinal dorsal hornDorsal root gangliaChemoattractant protein-1Novel pharmacologic strategiesPaclitaxel-treated animalsNumerous rodent modelsLung cancer cellsPlace preference paradigmMonoacylglycerol lipase inhibitorsIntrinsic rewarding effectsPhospho-p38 MAPKMechanical allodyniaNeuropathic pain
2016
Diacylglycerol lipase β inhibition reverses nociceptive behaviour in mouse models of inflammatory and neuropathic pain
Wilkerson J, Ghosh S, Bagdas D, Mason B, Crowe M, Hsu K, Wise L, Kinsey S, Damaj M, Cravatt B, Lichtman A. Diacylglycerol lipase β inhibition reverses nociceptive behaviour in mouse models of inflammatory and neuropathic pain. British Journal Of Pharmacology 2016, 173: 1678-1692. PMID: 26915789, PMCID: PMC4842918, DOI: 10.1111/bph.13469.Peer-Reviewed Original ResearchConceptsChronic constrictive injuryNeuropathic pain modelWild-type miceAllodynic responsesInflammatory painPain modelLPS modelSide effectsExpression of LPSDiscernible side effectsUntoward side effectsPro-inflammatory responseEvidence of toleranceSites of inflammationConstrictive injuryMechanical allodyniaIntraplantar injectionNeuropathic painPathological painInflammatory mediatorsMouse peritoneal macrophagesLocus of actionNociceptive behaviorSciatic nerveAllodynia
2014
Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice
Bagdas D, Muldoon P, Zhu A, Tyndale R, Damaj M. Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. Neuropharmacology 2014, 85: 67-72. PMID: 24859605, PMCID: PMC4106981, DOI: 10.1016/j.neuropharm.2014.05.006.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnxietyAryl Hydrocarbon HydroxylasesConditioning, PsychologicalCytochrome P450 Family 2Disease Models, AnimalDose-Response Relationship, DrugEnzyme InhibitorsHyperalgesiaMaleMecamylamineMethoxsalenMice, Inbred ICRMotor ActivityNicotineNicotinic AgonistsNicotinic AntagonistsRewardSeverity of Illness IndexSubstance Withdrawal SyndromeTobacco Use DisorderConceptsNicotine plasma levelsWithdrawal signsPlasma levelsAdministration of methoxsalenEffect of methoxsalenNicotine dependence behaviorsNicotine replacement therapyChronic nicotine infusionDependence-related behaviorsDrug elimination ratePlace preference testMetabolism of nicotineReward-like propertiesLack of enhancementSpontaneous withdrawalNicotine withdrawalReplacement therapyNicotine preferenceLow doseHigh doseNicotine infusionMouse CYP2A5CPP testActive nicotineNicotine levels